logo-loader
viewNewron Pharmaceuticals, S.p.A.

Newron Pharmaceuticals focusing on treating Rett syndrome with drug acquired from Merck

Newron Pharmaceuticals SpA (SIX:NWRN) CEO Stefan Weber sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Italian company’s flagship drug xadago has received marketing authorization to treat Parkinson’s disease in the EU, Switzerland, the US, Australia, Canada, Brazil, and Colombia and is commercialized by Newron’s partner Zambon.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Carube Copper readies for next stage of company as C3 Metals

C3 Metals (CVE: CCCM) Executive Chairman Tony Manini joined Steve Darling from Proactive Vancouver to share news the company is going forward under the name C3 Metals Corp and with a new ticker CCCM on the TSX Venture Exchange. Manini telling Proactive why they made the name and ticker change...

7 minutes ago

2 min read